Northwell Health Labs

$\Box NEW TEST \ \ \Box TEST \ CHANGE$

NOTIFICATION DATE: 08/22/2024 EFFECTIVE DATE: 09/10/2024

Thyroid Peroxidase Antibodies (TPO)

Effective 9/10/2024, Northwell Health Laboratories will transition to a new assay methodology for the measurement of thyroid peroxidase autoantibodies (anti-TPO). The current chemiluminescence immunoassay (Siemens IMMULITE 2000 Anti-TPO Ab) will be replaced with an electrochemiluminescence immunoassay (Roche ELECSYS Anti-TPO).

Thyroid peroxidase is a crucial enzyme in the biosynthesis of thyroid hormones and is a fundamental component of normal thyroid function. The presence of autoantibodies directed against thyroid peroxidase (anti-TPO) is often indicative of autoimmune thyroid diseases. Specifically, anti-TPO autoantibodies are elevated in >90% of Hashimoto's disease (autoimmune thyroiditis) patients and 50-80% of Graves' disease patients.

An in-house method comparison study conducted at Northwell Health Laboratories demonstrated acceptable qualitative clinical concordance between the two assays. *However, direct comparison of quantitative result values between the two assays is not feasible due to variability in immunoassay design and antibody epitope recognition.* Please be aware of this change in methodology when reviewing patient histories and previous anti-TPO results, particularly for patients undergoing serial monitoring. Adjustments in clinical interpretation is necessary, as highlighted in the table below.

Test Requirement	New	Previous
Methodology	Electrochemiluminescence Immunoassay	Chemiluminescence immunoassay
Assay Manufacturer	Roche Diagnostics	Siemens Healthineers
Reference Interval	≤34 IU/mL: Negative >34 IU/mL: Positive	≤35 IU/mL: Negative >35 IU/mL: Positive
Specimen Collection	1 mL Serum (0.5 mL minimum)	1 mL Serum (0.5 mL minimum)
Computer Interface Code	PDM #5915422	PDM #5915422
Test Order	ТРО	ТРО